Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway

被引:17
作者
Ando, Koji [1 ]
Shah, Ankur K. [1 ]
Sachdev, Vibhu [1 ]
Kleinstiver, Benjamin P. [2 ,3 ]
Taylor-Parker, Julian [1 ]
Welch, Moira M. [2 ]
Hu, Yiheng [4 ]
Salgia, Ravi [5 ]
White, Forest M. [6 ]
Parvin, Jeffrey D. [4 ]
Ozonoff, Al [7 ]
Rameh, Lucia E. [8 ]
Joung, J. Keith [2 ,3 ]
Bharti, Ajit K. [1 ]
机构
[1] Boston Univ, Sch Med, Dept Med, Div Hematol Oncol, Boston, MA 02118 USA
[2] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA USA
[3] Harvard Med Sch, Dept Pathol, Boston, MA USA
[4] Ohio State Univ, Ctr Comprehens Canc, Dept Biomed Informat, Columbus, OH 43210 USA
[5] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
[6] MIT, Koch Inst Integrat Canc Res, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA
[7] Boston Childrens Hosp, Ctr Patient Safety & Qual Res, Boston, MA USA
[8] Boston Univ, Sch Med, Dept Med, Obes Res Ctr, Boston, MA 02118 USA
基金
加拿大自然科学与工程研究理事会; 美国国家卫生研究院;
关键词
topoisomerase I; BRCA1; DNAPK; PTEN; ubiquitin proteasome pathway; DEPENDENT PROTEIN-KINASE; DOUBLE-STRAND BREAKS; DNA-DAMAGE; DRUG CAMPTOTHECIN; CATALYTIC SUBUNIT; MAMMALIAN-CELLS; LUNG-CANCER; E3; LIGASE; REPAIR; PHOSPHORYLATION;
D O I
10.18632/oncotarget.16376
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Proteasomal degradation of topoisomerase I (topoI) is one of the most remarkable cellular phenomena observed in response to camptothecin (CPT). Importantly, the rate of topoI degradation is linked to CPT resistance. Formation of the topoI-DNA-CPT cleavable complex inhibits DNA re-ligation resulting in DNA-double strand break (DSB). The degradation of topoI marks the first step in the ubiquitin proteasome pathway (UPP) dependent DNA damage response (DDR). Here, we show that the Ku70/Ku80 heterodimer binds with topoI, and that the DNA-dependent protein kinase (DNA-PKcs) phosphorylates topoI on serine 10 (topoI-pS10), which is subsequently ubiquitinated by BRCA1. A higher basal level of topoI-pS10 ensures rapid topoI degradation leading to CPT resistance. Importantly, PTEN regulates DNA-PKcs kinase activity in this pathway and PTEN deletion ensures DNA-PKcs dependent higher topoI-pS10, rapid topoI degradation and CPT resistance.
引用
收藏
页码:43733 / 43751
页数:19
相关论文
共 56 条
[41]  
RUBIN E, 1995, CLIN CANCER RES, V1, P269
[42]  
Rubin EH, 1996, CANC TREAT RES, V87, P243
[43]   A DNA-Damage Selective Role for BRCA1 E3 Ligase in Claspin Ubiquitylation, CHK1 Activation, and DNA Repair [J].
Sato, Ko ;
Sundaramoorthy, Elayanambi ;
Rajendra, Eeson ;
Hattori, Hiroyoshi ;
Jeyasekharan, Anand D. ;
Ayoub, Nabieh ;
Schiess, Ralph ;
Aebersold, Ruedi ;
Nishikawa, Hiroyuki ;
Sedukhina, Anna S. ;
Wada, Haruka ;
Ohta, Tomohiko ;
Venkitaraman, Ashok R. .
CURRENT BIOLOGY, 2012, 22 (18) :1659-1666
[44]   Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes [J].
Shao, RG ;
Cao, CX ;
Zhang, HL ;
Kohn, KW ;
Wold, MS ;
Pommier, Y .
EMBO JOURNAL, 1999, 18 (05) :1397-1406
[45]   DNA Double-Strand Break Repair Pathway Choice Is Directed by Distinct MRE11 Nuclease Activities [J].
Shibata, Atsushi ;
Moiani, Davide ;
Arvai, Andrew S. ;
Perry, Jefferson ;
Harding, Shane M. ;
Genois, Marie-Michelle ;
Maity, Ranjan ;
van Rossum-Fikkert, Sari ;
Kertokalio, Aryandi ;
Romoli, Filippo ;
Ismail, Amani ;
Ismalaj, Ermal ;
Petricci, Elena ;
Neale, Matthew J. ;
Bristow, Robert G. ;
Masson, Jean-Yves ;
Wyman, Claire ;
Jeggo, Penny A. ;
Tainer, John A. .
MOLECULAR CELL, 2014, 53 (01) :7-18
[46]   Ku86 modulates DNA topoisomerase I-mediated radiosensitization, but not cytotoxicity, in mammalian cells [J].
Shih, SJ ;
Erbele, T ;
Chen, AY .
CANCER RESEARCH, 2005, 65 (20) :9194-9199
[47]   The mechanism of topoisomerase I poisoning by a camptothecin analog [J].
Staker, BL ;
Hjerrild, K ;
Feese, MD ;
Behnke, CA ;
Burgin, AB ;
Stewart, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (24) :15387-15392
[48]   Predicting drug sensitivity and resistance:: Profiling ABC transporter genes in cancer cells [J].
Szakács, G ;
Annereau, JP ;
Lababidi, S ;
Shankavaram, U ;
Arciello, A ;
Bussey, KJ ;
Reinhold, W ;
Guo, YP ;
Kruh, GD ;
Reimers, M ;
Weinstein, JN ;
Gottesman, MM .
CANCER CELL, 2004, 6 (02) :129-137
[49]   Gene mutation analysis and quantitation of DNA topoisomerase I in previously untreated non-small cell lung carcinomas [J].
Takatani, H ;
Oka, M ;
Fukuda, M ;
Narasaki, F ;
Nakano, R ;
Ikeda, K ;
Terashi, K ;
Kinoshita, A ;
Soda, H ;
Kanda, T ;
Schneider, E ;
Kohno, S .
JAPANESE JOURNAL OF CANCER RESEARCH, 1997, 88 (02) :160-165
[50]  
Tonotsuka N, 2006, INT J MOL MED, V18, P441